Jasbir Seehra, Ph.D.
Jasbir Seehra is the founding CEO of Keros Therapeutics. Jas worked with the academic founders and Pontifax in putting together the strategy and in-licensing of the founding technology. Jas brings more than 30 years of scientific, strategic and operational experience in Biotech industry.

Prior to Keros, Dr. Seehra was the CSO at Ember Therapeutics, founded by Third Rock Ventures. In 2003, Jas co-founded Acceleron Pharma, focused on biologics inhibiting the TGFb superfamily and served as CSO to the end of 2010. Jas hired the research team that discovered multiple products and manufacturing teams and oversaw the discovery and development of multiple products targeting muscle strength, bone loss and anemia. As founder and member of the executive team, Jas helped raise more than $200M capital from venture fund and corporate partnerships with Celgene and Shire.

Jas spent 20 years at Genetics Institute and then Wyeth Pharmaceutics starting in 1983 as a bench scientist, holding numerous positions with increasing responsibility. Dr. Seehra successfully built the small molecule drug discovery capability at Genetics Institute and after the merger with Wyeth, he led the small molecule lead discovery as VP of Biological Chemistry.

He received his undergraduate and graduate degrees in Biochemistry from the University of Southampton UK. Dr. Seehra completed his postdoctoral work with Professor H. Gobind Khorana at the Massachusetts Institute of Technology. Dr. Seehra has numerous publications and is an inventor on more than 70 patents.
Jenn Lachey, Ph.D.
Jenn Lachey joined Keros Therapeutics in 2016 as the Vice President of Pharmacology. She brings more than 12 years of industry experience in drug discovery and development across many therapeutic areas, including neuromuscular disease, aging, obesity and diabetes, infectious disease and inflammation.

Jenn has previously worked at Seres Therapeutics where she evaluated the efficacy of microbiome therapeutics and contributed to the clinical development of multiple unique programs. Prior to Seres, she led the pharmacology effort at Ember Therapeutics, a company focused on targeting brown fat for the treatment of obesity and diabetes.

Jenn started her career in biotech at Acceleron Pharma where she characterized the effects of a soluble activin receptor type IIB Fc-fusion protein on muscle, bone and fat in a variety of preclinical models, including Duchenne muscular dystrophy, androgen deficiency and diet-induced obesity.

Jenn received her Ph.D. in Neurobiology from University of Cincinnati before relocating to Boston to complete her post-doctoral training at Beth Israel Deaconess Medical Center.